Trial Profile
A Phase II Study of BAY 43-9006 [sorafenib] in Relapsed Chronic Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 21 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jul 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.